An entrepreneurial company based in Bergens goes public: Develops state-of-the-art technology for diabetes

– Our technology will help solve the biggest lifestyle-related diseases we face, "said Christian Saure, president of Lifecare.

Half a billion people will have to measure their blood sugar by 2030.

"Today, many have to rely on traditional solutions that can be tried at the same time, uncomfortable and expensive, "writes the company in a press release. 19659004] Lifecare wants to offer people with diabetes a better solution.

– People with diabetes should carefully monitor blood sugar levels and be controlled by the individual to get the right amount of insulin at the right time. According to President Christian Saure in his press release, many diabetics want a modern tool with new blood glucose monitoring features, less expensive, more accurate and more comfortable

Lifecare researches and develops a miniature sensor for continuous monitoring glucose. to trade outstanding shares on Merkur Market under the symbol "LIFE-ME."

Read also: Sensor saves life: Trondheim medtech startup collects 23 million from the EU

Glucose Sensor

– Spring The technology will be able to help solve the most major lifestyle diseases that we face, "said Saure

Lifecare researches and develops Sencell, an implantable glucose sensor injected under the skin of the arm. The goal is that the miniature sensor can be in the body for at least six months, "says Rune Frisvold, CEO of Lifecares – and explains further:

– The sensor detects changes in glucose levels at the osmotic pressure. We can read glucose levels continuously. These levels will be able to communicate relentlessly to your doorbell or your phone that is available.

Rune Frisvold is the CEO of Lifecare and the management includes Prof. Andreas Pfützner, MD, Ph.D., Scientific Director (CSO) and Dr. Sanja Ramljak Scientific Project Manager

The board of directors includes Christian Saure, chairman of the board of directors; Christian Hysing-Dahl, member of the board of directors; and Joacim Holter, member of the board of directors.

– In addition, we will complete clinical trials, seek European approval and complete the "working prototype" for less than three years, says Frisvold

See also: Sarsia Seed to Entrepreneurs of health and energy